Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI310 + sintilimab
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IBI310 + sintilimab is a combination immunotherapy regimen consisting of two monoclonal antibodies developed by Innovent Biologics. IBI310 is an anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody, while sintilimab is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. This dual immune checkpoint blockade targets both CTLA-4 and PD-1 pathways to enhance antitumor immune responses. The combination has been investigated in multiple cancer types, including non-small-cell lung cancer (NSCLC), microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer, advanced melanoma, hepatocellular carcinoma (HCC), and cervical cancer. Clinical studies have shown promising efficacy and manageable safety profiles in these indications[1][3][5][7]. The regimen has received Breakthrough Therapy Designation in China for advanced cervical cancer and is under regulatory review as neoadjuvant therapy for MSI-H/dMMR colon cancer[2][8].
- Brand names
- None
- Other names
- None
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on IBI310 + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI310 + sintilimab.